Final answer:
CP-101,606 (Traxoprodil) has the weakest affinity for the dopamine D2-like receptor.
Step-by-step explanation:
The neuroleptic with the weakest affinity for the dopamine D2-like receptor is CP-101,606 (Traxoprodil). This compound is targeted to the NR2B subunit of the NMDA receptor and has been shown to treat both Parkinsonian and dyskinetic symptoms in animal models of Parkinson's disease. However, in human trials, it only appeared to treat dyskinetic symptoms.